Learn About Neuromyelitis Optica

What is the definition of Neuromyelitis Optica?

Neuromyelitis optica is an autoimmune disorder that affects the nerves of the eyes and the central nervous system, which includes the brain and spinal cord. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In neuromyelitis optica, the autoimmune attack causes inflammation of the nerves, and the resulting damage leads to the signs and symptoms of the condition.

What are the causes of Neuromyelitis Optica?

No genes associated with neuromyelitis optica have been identified. However, a small percentage of people with this condition have a family member who is also affected, which indicates that there may be one or more genetic changes that increase susceptibility. It is thought that the inheritance of this condition is complex and that many environmental and genetic factors are involved in the development of the condition.

How prevalent is Neuromyelitis Optica?

Neuromyelitis optica affects approximately 1 to 2 per 100,000 people worldwide. Women are affected by this condition more frequently than men.

Is Neuromyelitis Optica an inherited disorder?

Neuromyelitis optica is usually not inherited. Rarely, this condition is passed through generations in families, but the inheritance pattern is unknown.

Who are the top Neuromyelitis Optica Local Doctors?
Elite in Neuromyelitis Optica
Elite in Neuromyelitis Optica

University Of Virginia Physicians Group

1221 Lee St, 
Charlottesville, VA 
Languages Spoken:
English, Hebrew
Accepting New Patients
Offers Telehealth

Brian Weinshenker is a Neurologist in Charlottesville, Virginia. Dr. Weinshenker is rated as an Elite provider by MediFind in the treatment of Neuromyelitis Optica. His top areas of expertise are Transverse Myelitis, Neuromyelitis Optica, Optic Neuritis, and Multiple Sclerosis (MS). Dr. Weinshenker is currently accepting new patients.

Elias Sotirchos
Elite in Neuromyelitis Optica
Elite in Neuromyelitis Optica

Johns Hopkins Outpatient Center

Baltimore, MD 
Languages Spoken:
English, Greek
Offers Telehealth

Elias Sotirchos, M.D., specializes in the diagnosis, management and treatment of neuroimmunological disorders that involve the central nervous system, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). His research focuses on developing and validating novel imaging and blood-based biomarkers of these conditions, and clinical trials of experimental therapeutic agents. Dr. Sotirchos earned his medical degree from the National and Kapodistrian University of Athens and subsequently completed his internship and neurology residency training at The Johns Hopkins Hospital. He then pursued advanced clinical and research training in neuroimmunology at Johns Hopkins as a National MS Society Sylvia Lawry Fellow. Dr. Sotirchos is rated as an Elite provider by MediFind in the treatment of Neuromyelitis Optica. His top areas of expertise are Optic Neuritis, Multiple Sclerosis (MS), Neuromyelitis Optica, and Transverse Myelitis.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Neuromyelitis Optica
Distinguished in Neuromyelitis Optica

Duke Neurological Disorders Clinic - Clinic 1L

40 Duke Medicine Cir, 
Durham, NC 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

F Lee Hartsell Iii is a Neurologist in Durham, North Carolina. Dr. Lee Hartsell Iii is rated as a Distinguished provider by MediFind in the treatment of Neuromyelitis Optica. His top areas of expertise are Neuromyelitis Optica, Optic Neuritis, Multiple Sclerosis (MS), and Relapsing Multiple Sclerosis (RMS). Dr. Lee Hartsell Iii is currently accepting new patients.

What are the latest Neuromyelitis Optica Clinical Trials?
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapsed / Refractory Neurological Autoimmune Diseases

Summary: This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study

Summary: The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to deve...

Who are the sources who wrote this article ?

Published Date: March 01, 2015
Published By: National Institutes of Health